Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Hydroxyzine
4 evidence topics · 4 sources
FDA-approved indication
CANMAT guideline: second-line agent
“Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“however, clinical experience with this agent in the treatment of GAD remains limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review of hydroxyzine
“We included five studies in the review with a total of 884 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD (odds ratio (OR) 0.30, 95% CI 0.15 to 0.58)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In terms of side effects, hydroxyzine was associated with a higher rate of sleepiness/drowsiness than the active comparators (OR 1.74, 95% CI 0.86 to 3.53). There was, however, a high risk of bias in the included studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Even though more effective than placebo, due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first‐line treatment in GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote